Outcome of patients with intracranial non-germinomatous germ cell tumors—lessons from the SIOP-CNS-GCT-96 trial
Neuro-Oncology2017Vol. 19(12), pp. 1661–1672
Citations Over TimeTop 10% of 2017 papers
Gabriele Calaminus, Didier Frappaz, Rolf D. Kortmann, Barbara Krefeld, Frank Saran, Torsten Pietsch, Alexandre Vasiljevic, Maria Luisa Garrè, Umberto Ricardi, Jillian R. Mann, U. Göbel, Claire Alapetite, Matthew J. Murray, James C. Nicholson
Abstract
In localized malignant NGGCT, craniospinal radiotherapy could be avoided without increased relapses outside the radiotherapy field. Chemotherapy and craniospinal radiotherapy remain the gold standard for metastatic disease.
Related Papers
- → Ifosfamide with mesna uroprotection and etoposide in recurrent, refractory acute leukemia in childhood: A pediatric oncology group study(1993)6 cited
- → A Phase I/II Study of a 72‐h Continuous Infusion of Etoposide in Advanced Soft Tissue Sarcoma(1997)5 cited
- → Ifosfamide and Etoposide Salvage Treatment in Advanced Ovarian Cancer(1991)5 cited
- → Etoposide and etoposide-ifosfamide therapy for refractory testicular tumors(1982)28 cited
- → Ifosfamide and etoposide as salvage therapy for non‐Hodgkin's lymphoma(1986)12 cited